Indian firms fear US generic user fee would raise the cost of business
This article was originally published in Scrip
The Indian generic industry has reacted with measured optimism to the recent US FDA-industry agreement on generic drug user fees (GDUF), with some experts arguing that there are currently more questions than answers on the proposed fee-based programme's workability.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.